Design Therapeutics Inc (DSGN) Stock Price, Quote & News

Company Profile

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progr...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 293 4900

Website: www.designtx.com

Address:

6005 Hidden Valley Road, Suite 110, Carlsbad, United States

erevnon Mar. 16 at 2:55 PM

Jefferies initiates coverage on Design Therapeutics $DSGN at Buy rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

DonCorleone77 Mar. 16 at 3:06 AM

$DSGN Design Therapeutics initiated with a Buy at Jefferies Jefferies analyst Faisal Khurshid initiated coverage of Design Therapeutics with a Buy rating and $15 price target. The firm believes the company's DT-216P2 readout in the second half of 2026 can deliver a meaningful frataxin signal in Friedreich ataxia. The analyst sees upside on the news, saying the readout is "more de-risked than appreciated" given that the Phase 1 already showed proof-of-mechanism, and the new Phase 2 formulation "solves the exposure problem.

0 · Reply

erevnon Mar. 10 at 2:16 PM

RBC Capital maintains Design Therapeutics $DSGN at Outperform and raises the price target from $13 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

d_risk Mar. 9 at 8:54 PM

$DSGN - Design Therapeutics Inc - 10K - Updated Risk Factors DSGN’s risk profile now spotlights heavier reliance on biomarker-driven trials, expanded early-stage pipeline (DT-216P2, DT-168, DT-818) with regulatory holds and complex PK/route issues, heightened exposure to global trade, tariffs, China/biotech sanctions and NDAA limits, plus increased vulnerability to shifting US/EU pricing and coverage reforms. #BiotechnologySector #BiomarkerTrials #RegulatoryRisks #GlobalTradeExposure #PricingReforms 🟢 Added 🟠 Removed https://d-risk.ai/DSGN/10-K/2026-03-09

0 · Reply

BillionerOfKing Mar. 2 at 10:54 PM

$DSGN Current Stock Price: $10.24 Contracts to trade: $12.0 DSGN Mar 20 2026 Call Entry: $0.63 Exit: $1.05 ROI: 67% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OfficialStocktwitsUser Feb. 27 at 2:38 AM

$DSGN RSI: 63.27, MACD: 0.2105 Vol: 0.26, MA20: 10.30, MA50: 9.87 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

LunarCycleTrader Feb. 4 at 3:59 PM

$DSGN is a design or engineering services company; its revenue is project-based and sensitive to capital spending in its client industries.

0 · Reply

BillionerOfKing Jan. 27 at 6:09 PM

$DSGN Current Stock Price: $10.66 Contracts to trade: $10 DSGN Feb 20 2026 Call Entry: $1.00 Exit: $1.98 ROI: 98% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

notreload_ai Jan. 7 at 2:26 PM

$REGN , $ERAS , $TARA , $DSGN , $ORIC ... Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities. https://notreload.xyz/biotech-upgrades-regeneron-erasca-tara-dsgn-oric/

0 · Reply

Magic8BallResponse Jan. 5 at 2:55 PM

$DSGN Give me a 7!

0 · Reply

Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates

Feb 18, 2026, 8:00 AM EST - 26 days ago

Design Therapeutics to Participate in Upcoming Investor Conferences

Nov 5, 2025, 4:01 PM EST - 4 months ago

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

Sep 10, 2025, 4:01 PM EDT - 6 months ago

Design Therapeutics Appoints Justin Gover to Board of Directors

Sep 5, 2025, 3:07 AM EDT - 6 months ago

Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript

Aug 27, 2025, 8:00 AM EDT - 7 months ago

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Aug 7, 2025, 4:01 PM EDT - 7 months ago

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

Jun 4, 2025, 7:00 AM EDT - 10 months ago

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

May 28, 2025, 8:00 AM EDT - 10 months ago

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

May 13, 2025, 8:00 AM EDT - 10 months ago

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

May 7, 2025, 4:01 PM EDT - 11 months ago

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

May 1, 2025, 8:00 AM EDT - 11 months ago

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

Apr 21, 2025, 4:01 PM EDT - 11 months ago

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

Apr 17, 2025, 8:00 AM EDT - 11 months ago

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

Mar 10, 2025, 7:07 AM EDT - 1 year ago

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Design Therapeutics to Participate in Leerink's Global Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 1 year ago

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Nov 7, 2024, 4:01 PM EST - 1 year ago

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

May 8, 2024, 4:05 PM EDT - 2 years ago

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

May 7, 2024, 6:30 AM EDT - 2 years ago

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Mar 19, 2024, 8:44 PM EDT - 2 years ago

Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:01 PM EDT - 2 years ago

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 12, 2024, 6:30 AM EDT - 2 years ago

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Nov 13, 2023, 4:05 PM EST - 2 years ago

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Aug 15, 2023, 8:17 AM EDT - 2 years ago

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

May 31, 2023, 6:30 AM EDT - 3 years ago

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

May 9, 2023, 4:05 PM EDT - 3 years ago

Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

Apr 24, 2023, 6:30 AM EDT - 3 years ago

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023

Mar 14, 2023, 4:05 PM EDT - 3 years ago

Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 8, 2023, 6:30 AM EST - 3 years ago

Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

Dec 7, 2022, 4:01 PM EST - 3 years ago

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

Nov 3, 2022, 4:05 PM EDT - 3 years ago

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Oct 17, 2022, 4:05 PM EDT - 3 years ago

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

Sep 22, 2022, 6:30 AM EDT - 3 years ago

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

Aug 8, 2022, 4:05 PM EDT - 3 years ago

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

Aug 3, 2022, 6:30 AM EDT - 3 years ago

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

Jun 1, 2022, 6:30 AM EDT - 4 years ago

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

May 9, 2022, 4:05 PM EDT - 4 years ago

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

Mar 30, 2022, 6:30 AM EDT - 4 years ago

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

Mar 10, 2022, 4:02 PM EST - 4 years ago

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Mar 9, 2022, 6:30 AM EST - 4 years ago

Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022

Feb 28, 2022, 4:05 PM EST - 4 years ago

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Feb 10, 2022, 6:30 AM EST - 4 years ago

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Feb 1, 2022, 4:05 PM EST - 4 years ago

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

Jan 19, 2022, 12:51 PM EST - 4 years ago

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

erevnon Mar. 16 at 2:55 PM

Jefferies initiates coverage on Design Therapeutics $DSGN at Buy rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

DonCorleone77 Mar. 16 at 3:06 AM

0 · Reply

erevnon Mar. 10 at 2:16 PM

RBC Capital maintains Design Therapeutics $DSGN at Outperform and raises the price target from $13 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

d_risk Mar. 9 at 8:54 PM

0 · Reply

BillionerOfKing Mar. 2 at 10:54 PM

0 · Reply

OfficialStocktwitsUser Feb. 27 at 2:38 AM

0 · Reply

LunarCycleTrader Feb. 4 at 3:59 PM

$DSGN is a design or engineering services company; its revenue is project-based and sensitive to capital spending in its client industries.

0 · Reply

BillionerOfKing Jan. 27 at 6:09 PM

0 · Reply

notreload_ai Jan. 7 at 2:26 PM

0 · Reply

Magic8BallResponse Jan. 5 at 2:55 PM

$DSGN Give me a 7!

0 · Reply

RevenueRadius Dec. 25 at 5:12 PM

$DSGN What matters next is the company’s ability to build a predictable delivery rhythm. The business must show that scaling does not introduce uncontrolled risk. Failure to deliver would likely trigger renewed valuation compression. Absent confirmation, volatility is likely to persist.

0 · Reply

SuperGreenToday Dec. 10 at 2:53 AM

$DSGN Share Price: $9.27 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.14 – $0.17 Potential Upside: 57% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

JarvisFlow Dec. 3 at 1:40 PM

Leerink Partners has adjusted their stance on Design Therapeutics ( $DSGN ), setting the rating to Outperform with a target price of 7 → 14.

0 · Reply

JarvisFlow Nov. 20 at 3:01 PM

RBC Capital has updated their rating for Design Therapeutics ( $DSGN ) to Outperform with a price target of 13.

0 · Reply

notreload_ai Nov. 20 at 11:52 AM

RBC Capital upgrades $DSGN to Outperform with a new $13 price target, citing promising 2026 milestones, positive data potential, and long-term revenue upside. https://notreload.xyz/rbc-upgrades-design-therapeutics-on-2026-outlook/

0 · Reply

JarvisFlow Nov. 6 at 3:48 PM

RBC Capital updates rating for Design Therapeutics ( $DSGN ) to Sector Perform, target set at 5 → 6.

0 · Reply

d_risk Nov. 5 at 9:31 PM

$DSGN - Design Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors DSGN’s risk factors now detail clinical trial setbacks including FDA clinical hold, side effect concerns, and reformulation of DT-216; expanded regulatory, IP, and competitive threats; new risks from patent law changes, licensing disputes, anti-corruption laws, anti-takeover provisions, and potential stock volatility from insider sales. #Biotechnology #StockVolatility #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/DSGN/10-Q/2025-11-05

0 · Reply

RunnerSignals Oct. 27 at 8:37 PM

$DQ $DSGN $SNAL $ARQQ $JANX finally shake off the sideways blues with big moves and strong volume

0 · Reply

Quantumup Oct. 6 at 1:56 PM

Citizens reiterated $LRMR at Market Outperform/$18 after hosting a call w/ the CEO of the Friedreich's Ataxia Research Alliance (FARA), Jennifer Farmer, on Friday, who said, 'The Patient Community Believes Nomlabofusp's Potential Benefits Outweigh Its Risks' $BIIB $LXEO $PTCT $DSGN Citizens JMP said:

0 · Reply

Quantumup Oct. 2 at 2:27 PM

Oppenheimer lowered $LRMR's price target to $21 from $26 to reflect the share count change following Larimar's recent capital raise; reiterated at Outperform. $BIIB $LXEO $PTCT $DSGN Oppenheimer said: Larimar reported positive results from the 50mg OLE cohort of nomla, supporting its use as the potentially first disease-modifying treatment in Friedreich's Ataxia (FA). Data were positive, demonstrating all OLE patients at 6-months reached skin frataxin levels over 50% of healthy volunteers along with improvements in clinical outcomes, though the seven cases of reported anaphylaxis in the OLE drew concern; while a potential concern, anaphylaxis is manageable. OPY sees LRMR's rebound from the previous day's selloff reflecting nomla's favorable benefit-risk profile in FA and still sees a buying opportunity ahead of the Q2 2026 BLA submission, followed by a potential early 2027 launch.

0 · Reply

Quantumup Sep. 16 at 7:23 PM

Guggenheim reiterated $LRMR at a Buy rating and a $26 PT after its FDA Expert (fmr. Director of the Division of Pharmacometrics at the FDA) Expressed High Conviction in $LRMR's Regulatory Case and Noted $BIIB's Qalsody as One of Several of His Case Points. [ $PTCT $LXEO $DSGN] Guggenheim said in its note:

1 · Reply

NVDAMillionaire Sep. 4 at 8:47 AM

$DSGN Really good write-up that perfectly summarizes DSGN's present situation. So if you want to bring your DSGN knowledge up to date or just discover DSGN, this is required reading. https://beyondspx.com/quote/DSGN/design-therapeutics-unlocking-genomic-medicines-with-a-novel-small-molecule-approach-dsgn#analysis

0 · Reply

Market Cap	624.12M
Revenue (ttm)	0.00
Net Income (ttm)	-49.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	337,800
Avg Vol	258,478
Day's Range	N/A - N/A
Shares Out	61.67M
Stochastic %K	38%
Beta	1.63
Analysts	Strong Sell
Price Target	$14.60